NASDAQ: BHSTBioharvest Sciences Inc Stock
$1.46-0.05 (-3.31%)
Updated Sep 23, 2026
BHST Price
$1.46
Fair Value Price
N/A
Market Cap
$33.10M
52 Week Low
$1.45
52 Week High
$12.80
P/E
-2.86x
P/B
1.67x
P/S
1.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.48M
Earnings
-$11.07M
Gross Margin
59%
Operating Margin
-17.24%
Profit Margin
-31.2%
Debt to Equity
1.26
Operating Cash Flow
-$9M
Beta
0.69
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BHST Overview
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BHST's potential to beat the market
- BHST doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Food
Industry Rating
D
BHST
RankedUnranked of 46
RankedUnranked of 46
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $61.36 | A | |
| $179.15 | B | |
| $122.41 | B |
Be the first to know about important BHST news, forecast changes, insider trades & much more!
BHST News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BHST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BHST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BHST is poor value based on its book value relative to its share price (1.67x), compared to the US Packaged Foods industry average (1.51x)
P/B vs Industry Valuation
BHST is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BHST due diligence checks available for Premium users.
Valuation
BHST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.86x
Industry
7.74x
Market
48.4x
BHST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
1.51x
BHST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BHST's financial health
Profit margin
Revenue
$8.8M
Net Income
-$3.7M
Profit Margin
-42%
BHST's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BHST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$44.6M
Liabilities
$24.8M
Debt to equity
1.26
BHST's short-term assets ($26.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BHST's short-term assets ($26.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BHST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
-$568.0k
Financing
-$675.0k
BHST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BHST vs Food Stocks
Bioharvest Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.